Complement-targeted Therapeutics Market
Market Insights on Complement-targeted Therapeutics covering sales outlook, demand forecast & up-to-date key trends
Complement-targeted Therapeutics Market by Indication, Distribution Channel & Region - Forecast 2022 - 2032
Complement-targeted Therapeutics Market Outlook
The complement-targeted therapeutics market is expected to strengthen its roots in the global market at a strong CAGR of 22.9% between 2022 and 2032.
The global market holds a forecasted revenue of US$ 5.19 Bn in 2022 and is likely to cross US$ 33.20 Bn by the end of 2032.
The complement-targeted therapeutics market is anticipated to show promising growth prospects during the forecast period, expanding the complement-targeted therapeutics market share.
Attributes |
Details |
CAGR (2022-2032) |
22.9% |
Value (2022) |
US$ 5.19 Billion |
Value (2032) |
US$ 33.20 Billion |
Demand for complement-targeted therapeutics is on the surge as they are widely used in patients that have a weaker complement cascade because of deficiency of some proteins or comparatively lower concentration.
Growing chronic diseases are pushing the sales of complement-targeted therapeutics as these diseases lower the proteins and weaken the complement cascade.
The complement cascade is a composition of 30 proteins that is a defence against infection and is encouraging many to opt for the same, thereby spiking the demand for complement-targeted therapeutics.
The complement-targeted therapeutics help in creating an immune response to foreign particles entered into the body for a patient that has a complement cascade is weaker, fuelling the demand for complement-targeted therapeutics.
Covid-19 has pushed the sales of complement-targeted therapeutics forward as the number of patients with chronic diseases has risen up as post-covid-19, fuelling the demand for complement-targeted therapeutics.
Let us know your requirement to get
100% FREE customization
What are the Key Drivers and Restraints in the Complement-targeted Therapeutics Market
Demand for complement-targeted therapeutics is on the rise as complement-targeted therapeutics represent the vast potential for the mechanism by which the body responds to the infection.
The complement system eliminates particulate substances; furthermore, it also helps in modulating adaptive immune responses, thereby propelling the sales of complement-targeted therapeutics.
Complement-targeted therapeutics help in the normal mechanism of the immune system, fueling the sales of complement-targeted therapeutics.
There are a large number of clinical trials going on to evaluate the use of complement-targeted therapeutics in managing the body’s first response and normal immune system functioning.
With the increasing prevalence of immune system diseases and vast clinical research in complement-targeted therapeutics, it is expected to significantly fuel the demand for complement-targeted therapeutics.
The rising sales of complement-targeted therapeutics are also attributed to the growing prevalence of the geriatric population, whose body is comparatively more susceptible to infection due to a weak immune system.
The same is expected to drive the growth of complement-targeted therapeutics market share.
The increasing prevalence of chronic diseases is further expected to drive the demand for complement-targeted therapeutics.
However, a large proportion of the population living with complement deficiency goes undiagnosed, which may hamper the demand for complement-targeted therapeutics.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhich is the Biggest Region in the Complement-targeted Therapeutics Market
The global complement-targeted therapeutics market is expected to be dominated by North America due to higher product availability and is likely to witness a large number of sales of complement-targeted therapeutics.
Europe is expected to be the second most lucrative region and hold a considerable chunk of complement-targeted therapeutics market share owing to higher disease prevalence.
Latin America complement-targeted therapeutics market is expected to witness steady growth over the forecast period owing to increasing product availability in the region.
Asia-Pacific complement-targeted therapeutics market is expected to witness exponential growth over the forecast period owing to increasing product adoption for the treatment, fuelling the sales of complement-targeted therapeutics.
Middle East & Africa is expected to be the least lucrative region in the global complement-targeted therapeutics market due to least product adoption, expanding the complement-targeted therapeutics market share.
Who are the Key Players in the Complement-targeted Therapeutics Market
The key players in the complement-targeted therapeutics market are focusing on mergers and collaborations and the same is likely to fuel the sales of complement-targeted therapeutics.
Major players in the complement-targeted therapeutics market include Creative Biolabs, Complement UK, Novartis AG, Alexion Pharmaceuticals, PubMed Inc., Merck & Co., Inc., Pfizer Inc., Allergan plc, AbbVie.
Some of the recent developments in complement-targeted therapeutics market are as follows:
- Creative Biolabs has introduced its new series of complement-directed drug discovery that delivers full stack complement therapeutic services, fuelling the sales of complement-targeted therapeutics solutions.
- PubMed Inc. has launched its upgraded versions of complement-targeted therapeutics to cater different destructive capabilities for numerous diseases and pathological conditions, fuelling the sales of complement-targeted therapeutics.

An unified Market Research Subscription Platform, built for today’s disparate research needs.
Report Scope
Report Attribute |
Details |
Growth Rate |
CAGR of 22.9% from 2022 to 2032 |
Base year for estimation |
2021 |
Historical data |
2014 – 2020 |
Forecast period |
2022 – 2032 |
Quantitative units |
Revenue in USD Billion, volume in kilotons, and CAGR from 2022 to 2032 |
Report coverage |
Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis |
Segments covered |
Indication, Distribution Channel, Region |
Regional scope |
North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, and Middle East and Africa |
Country scope |
U.S.; Canada; Mexico; Germany; U.K.; France; Italy; Spain; Russia; Belgium; Poland; Czech Republic; China; India; Japan; Australia; Brazil; Argentina; Colombia; Saudi Arabia; UAE; Iran; South Africa |
Key companies profiled |
Creative Biolabs, Complement UK, Novartis AG, Alexion Pharmaceuticals, Inc. Merck & Co., Inc., Pfizer Inc., Allergan plc, AbbVie |
Customization scope |
Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs |
Frequently Asked Questions
North America holds the largest complement-targeted therapeutics market share owing to rapid growth of chronic diseases leading to a higher demand for complement-targeted therapeutics.
Key players holding substantial complement-targeted therapeutics market share include Creative Biolabs, Complement UK, Novartis AG, Alexion Pharmaceuticals, Inc. Merck & Co., Inc., Pfizer Inc., Allergan plc, and AbbVie.
Demand for complement-targeted therapeutics is likely to increase with their use in hospitals and healthcare units thereby thriving the sales of complement-targeted therapeutics in new markets.
NA
Let us know your requirement to get
100% FREE customization
NA
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystNA
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports